Table 1.
Activity of PSI-352938 in genotype 1a, 1b, and 2a subgenomic replicon cells and genotype 1a and 2a infectious virus system
| Cell-based assay and genotype | EC50 (μM) | EC90 (μM) |
|---|---|---|
| HCV replicona | ||
| 1b | 0.13 ± 0.076 | 0.51 ± 0.34 |
| 1a | 0.20 ± 0.12 | 0.74 ± 0.30 |
| 2a | 0.14 ± 0.040 | 0.35 ± 0.075 |
| Infectious HCVb | ||
| 1a | 0.28 ± 0.083 | 0.63 ± 0.018 |
| 2a | 0.39 ± 0.31 | 1.16 ± 0.64 |
a
Cells were treated with PSI-352938 for 4 days prior to determination of HCV inhibition. Quantitative real-time PCR or a luciferase-based reporter assay was used to quantify levels of HCV inhibition. Values are reported as averages of at least three independent experiments ± standard deviations.
b
Infectious foci were quantified using a primary HCV-core mouse monoclonal antibody reacted with a FITC-labeled secondary antibody. Values are reported as averages ± standard deviations of two independent experiments performed in duplicate.